FDA 483 - Bio-Recovery Inc. - July 24, 2018

An FDA inspection of Bio-Recovery Inc., an own label distributor in Minneapolis, MN, revealed significant quality control deficiencies. The firm failed to properly review documentation for quarantined products and did not conduct necessary tests for strength and contamination before releasing dietary supplements. These issues indicate a lack of adherence to established specifications and testing requirements for product release.